Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $28,037.00 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,438 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $28,037.00. Following the completion of the sale, the chief financial officer now owns 39,922 shares of the company’s stock, valued at $459,103. This trade represents a 5.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, May 2nd, Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34.
• On Monday, March 3rd, Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock. The shares were sold at an average price of $14.49, for a total transaction of $84,404.25.
• On Thursday, January 30th, Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35.

Nurix Therapeutics Stock Up 1.0 %

Shares of Nurix Therapeutics stock opened at $11.27 on Friday. The firm has a market cap of $859.18 million, a PE ratio of -3.90 and a beta of 2.23. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The business’s fifty day simple moving average is $12.03 and its 200-day simple moving average is $17.99.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The company had revenue of $18.45 million for the quarter, compared to analysts’ expectations of $12.78 million. During the same quarter in the prior year, the company posted ($0.76) earnings per share. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NRIX shares. Stifel Nicolaus lowered their price objective on Nurix Therapeutics from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, April 9th. Needham & Company LLC reiterated a “buy” rating and set a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday. Wells Fargo & Company decreased their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, April 9th. Morgan Stanley upped their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Three investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.44.

Hedge Funds Weigh In On Nurix Therapeutics

Hedge funds have recently made changes to their positions in the stock. US Bancorp DE lifted its stake in Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after purchasing an additional 842 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Nurix Therapeutics during the 4th quarter worth about $28,000. Aquatic Capital Management LLC purchased a new position in Nurix Therapeutics during the 4th quarter valued at about $87,000. Summit Investment Advisors Inc. grew its position in Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after acquiring an additional 877 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in Nurix Therapeutics during the fourth quarter worth about $164,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.